1. Home
  2. BLMN vs DSGN Comparison

BLMN vs DSGN Comparison

Compare BLMN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bloomin' Brands Inc.

BLMN

Bloomin' Brands Inc.

HOLD

Current Price

$10.23

Market Cap

975.2M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$15.62

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLMN
DSGN
Founded
1988
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
975.2M
853.8M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
BLMN
DSGN
Price
$10.23
$15.62
Analyst Decision
Hold
Strong Buy
Analyst Count
8
4
Target Price
$7.88
$15.25
AVG Volume (30 Days)
2.1M
448.0K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
4.99%
N/A
EPS Growth
106.71
N/A
EPS
1.01
N/A
Revenue
$4,213,346,000.00
N/A
Revenue This Year
$2.07
N/A
Revenue Next Year
$1.81
N/A
P/E Ratio
$10.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.19
$4.92
52 Week High
$12.63
$17.25

Technical Indicators

Market Signals
Indicator
BLMN
DSGN
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
BLMN
DSGN

About BLMN Bloomin' Brands Inc.

Bloomin Brands Inc is a casual dining restaurant company, with a portfolio of, differentiated restaurant concepts. Its restaurant portfolio includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill and Fleming's Prime Steakhouse & Wine Bar. Its restaurant concepts range in price point and degree of formality from casual (Outback Steakhouse and Carrabba's Italian Grill) to polished casual (Bonefish Grill) and fine dining (Fleming's Prime Steakhouse & Wine Bar). The U.S. segment includes all restaurants operating in the U.S. while franchised restaurants operating outside the U.S. are included in the international franchise segment.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: